# Boswellia papyrifera (Boswellia papyrifera (Del.) Hochst.)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/boswellia-papyrifera-boswellia-papyrifera-del-hochst
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Middle Eastern
**Also Known As:** paper-bark frankincense tree, African olibanum, Boswellia papyrifera (Boswellia papyrifera), Tigray frankincense, B. papyrifera, Sudanese frankincense, Boswellia papyrifera (Del.) Hochst.

## Overview

Boswellia papyrifera resin contains boswellic acids (totaling approximately 7.04% β-boswellic acids), stilbene glycosides, and triterpenes that inhibit key enzymes including phosphodiesterase I, xanthine oxidase, and prolyl endopeptidase. Preclinical and in vitro evidence supports its [anti-inflammatory](/ingredients/condition/inflammation), [antimicrobial](/ingredients/condition/immune-support), and anti-tuberculosis properties, with chloroform resin extracts demonstrating the highest antimicrobial potency among tested solvent fractions.

## Health Benefits

- **[Antimicrobial](/ingredients/condition/immune-support) and Anti-TB Activity**: Chloroform, petroleum ether, and ethanol extracts of B. papyrifera resin exhibit antimicrobial activity, with the chloroform fraction showing the broadest spectrum; traditional Arabic medicine employs the olibanum resin specifically against Mycobacterium tuberculosis-associated conditions.
- **[Anti-Inflammatory](/ingredients/condition/inflammation) Effects**: Boswellic acids, particularly β-keto-boswellic acid (β-KBA, 0.46%) and β-acetyl-11-keto-boswellic acid (β-AKBA), inhibit pro-inflammatory enzymes and pathways, reducing inflammatory signaling in a manner consistent with other Boswellia species' well-characterized mechanisms.
- **Enzyme Inhibition**: Stilbene glycosides isolated from the stem bark significantly inhibit phosphodiesterase I and xanthine oxidase, suggesting utility in conditions driven by [oxidative stress](/ingredients/condition/antioxidant) and aberrant cyclic nucleotide signaling.
- **Prolyl Endopeptidase Inhibition**: Triterpenic constituents including 3α-acetoxy-27-hydroxylup-20(29)-en-24-oic acid inhibit prolyl endopeptidase, an enzyme implicated in neuropeptide degradation and potentially relevant to neuroinflammatory and [cognitive](/ingredients/condition/cognitive) conditions.
- **Antioxidant Properties**: High concentrations of tannins (35.2%) and flavonoids (27.0%) in crude extracts contribute significant free-radical scavenging activity, protecting cells from oxidative damage through polyphenol-mediated mechanisms.
- **Analgesic Potential**: Consistent with broader Boswellia genus pharmacology and its traditional use in pain-associated conditions, boswellic acids from B. papyrifera may modulate pain pathways by suppressing leukotriene synthesis via 5-lipoxygenase inhibition.
- **[Hepatoprotective](/ingredients/condition/detox) Activity**: General bioactivities documented across Boswellia species, including immunosuppressant and hepatoprotective effects, are attributed to the boswellic acid fraction, though species-specific hepatoprotective data for B. papyrifera remain preliminary.

## Mechanism of Action

The stilbene glycosides of Boswellia papyrifera bark inhibit phosphodiesterase I, thereby elevating intracellular cyclic nucleotide levels and modulating downstream inflammatory and immune signaling, while concurrent inhibition of xanthine oxidase reduces uric acid and [reactive oxygen species](/ingredients/condition/antioxidant) production. Triterpenic boswellic acids, particularly β-AKBA, are understood across the Boswellia genus to competitively inhibit 5-lipoxygenase (5-LOX), blocking leukotriene B4 synthesis and attenuating neutrophil-mediated [inflammation](/ingredients/condition/inflammation); B. papyrifera's boswellic acid profile, which notably lacks β-boswellic acid entirely and contains relatively low β-KBA (0.46%), distinguishes its potency profile from B. serrata and B. sacra. Prolyl endopeptidase inhibition by lupane-type triterpenes reduces degradation of bioactive neuropeptides such as substance P, potentially contributing to analgesic and [neuroprotective effect](/ingredients/condition/cognitive)s. High tannin content (35.2%) provides additional astringent and [antimicrobial](/ingredients/condition/immune-support) mechanisms through protein precipitation and microbial membrane disruption.

## Clinical Summary

No species-specific clinical trials for Boswellia papyrifera were identified in the peer-reviewed literature at the time of this writing. The [anti-inflammatory](/ingredients/condition/inflammation) and analgesic properties of the Boswellia genus have been evaluated in RCTs primarily using B. serrata extract standardized to AKBA, with modest-to-moderate effect sizes in osteoarthritis (e.g., reductions in WOMAC pain scores) and ulcerative colitis, but these results cannot be directly applied to B. papyrifera due to its distinct phytochemical profile, including the complete absence of β-boswellic acid. The [antimicrobial](/ingredients/condition/immune-support) and anti-TB claims remain supported only by traditional use documentation and in vitro extract testing, with no controlled human efficacy or safety trials completed. Until dedicated clinical studies are conducted, the evidence for therapeutic application of B. papyrifera specifically remains preclinical and preliminary.

## Nutritional Profile

Boswellia papyrifera is consumed medicinally as a resin rather than as a food, and thus lacks a conventional macronutrient nutritional profile. The resin's lipophilic fraction (55–66% of total resin mass) is dominated by pentacyclic triterpenic boswellic acids, with total β-boswellic acids at approximately 7.04% of resin weight; notably, β-boswellic acid is completely absent and β-KBA is present at only 0.46%. The essential oil fraction (5–15%) provides monoterpenes including limonene (4.7%) and α-pinene (2.1%), and diterpenes including incensole acetate (1.7%) and incensole (0.7%). In crude plant extracts, alkaloids represent the highest phytochemical concentration at 44.6%, followed by tannins (35.2%) and flavonoids (27.0%), though these figures reflect total crude extract composition rather than isolated resin. A mucus-like polysaccharide fraction (12–23% of resin) contributes to viscosity and may affect gastrointestinal transit of bioactive compounds. Bioavailability of boswellic acids is enhanced by co-administration with dietary fats due to their lipophilic nature.

## Dosage & Preparation

- **Raw Resin (Traditional)**: Resin tears harvested by bark tapping are burned as incense or dissolved in warm water/oil for topical or oral traditional preparations; no standardized oral dose from clinical trials is established.
- **Ethanolic Extract (Research Grade)**: Used in laboratory studies; effective [antimicrobial](/ingredients/condition/immune-support) concentrations determined in vitro but not translated to human dosing guidelines.
- **Chloroform Extract**: Demonstrated the highest antimicrobial activity in in vitro testing; not available as a commercial supplement form due to solvent concerns.
- **Standardized Boswellic Acid Extract (Analogous Guidance)**: By extrapolation from B. serrata clinical data, standardized extracts providing 30–65% total boswellic acids at doses of 300–500 mg two to three times daily have been used in trials of other Boswellia species; no equivalent standard exists specifically for B. papyrifera.
- **Incense/Aromatherapy**: The essential oil fraction (5–15% of resin) contains monoterpenes (limonene 4.7%, α-pinene 2.1%) and diterpenes (incensole acetate 1.7%), used via inhalation in traditional ritual and therapeutic contexts.
- **Timing Note**: [Anti-inflammatory](/ingredients/condition/inflammation) boswellic acids from related species show improved absorption when taken with a fatty meal; this likely applies to B. papyrifera lipophilic fractions (55–66% of resin) by analogy.

## Safety & Drug Interactions

Boswellia papyrifera has no established human safety data from controlled clinical trials, and its safety profile must be inferred from traditional use patterns and the broader Boswellia genus literature; B. serrata extracts at conventional doses (300–1200 mg/day) are generally well tolerated with mild gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort reported in some trial participants. The high alkaloid content (44.6% in crude extracts) warrants caution, as alkaloid fractions can exhibit narrow therapeutic windows and hepatotoxic potential at elevated doses; however, refined resin preparations used traditionally contain far lower alkaloid concentrations. Potential drug interactions include inhibition of cytochrome P450 enzymes by boswellic acids, which may alter plasma levels of co-administered medications metabolized by CYP3A4 and CYP2C9, including immunosuppressants, anticoagulants, and antiretroviral drugs. Pregnancy and lactation safety data are absent for B. papyrifera specifically; the use of medicinal resin preparations is generally discouraged during pregnancy without medical supervision, given the uterotonic properties attributed to some frankincense constituents in traditional contexts.

## Scientific Research

The current evidence base for Boswellia papyrifera consists almost entirely of in vitro phytochemical studies and enzyme inhibition assays; no published human randomized controlled trials (RCTs) specifically for this species were identified in the available literature. Studies have characterized its boswellic acid profile (total β-boswellic acids ~7.04%), isolated and structurally confirmed novel stilbene glycosides with measurable phosphodiesterase I and xanthine oxidase inhibitory activity, and evaluated solvent-fraction [antimicrobial](/ingredients/condition/immune-support) activity against clinical pathogens. Ethnopharmacological surveys document traditional anti-TB use of the olibanum resin in Arabic and East African medicine, providing a biologically plausible rationale that has not yet been subjected to controlled clinical validation. Extrapolation from the considerably larger clinical literature on B. serrata (which has undergone RCTs in osteoarthritis and IBD) must be made cautiously given the distinct boswellic acid composition of B. papyrifera.

## Historical & Cultural Context

Boswellia papyrifera is one of the primary sources of African frankincense, traded across northeastern Africa and the Arabian Peninsula for millennia; its resin, known as 'olibanum' in Arabic medicine, appears in ancient trade records along the incense routes connecting sub-Saharan Africa to Egypt, Arabia, and the Mediterranean world. In traditional Arabic and East African medicine, the dried resin is employed internally for respiratory infections including conditions consistent with tuberculosis, and externally for wound healing and skin conditions, reflecting a deep ethnopharmacological heritage spanning at least two thousand years. Ethiopian and Eritrean traditional healers prepare resin decoctions and smoke inhalations for chest complaints, fevers, and [inflammatory](/ingredients/condition/inflammation) joint conditions, practices documented in regional ethnobotanical surveys. The species name 'papyrifera' (paper-bearing) refers to its distinctive papery, peeling bark, which makes it recognizable in the field and culturally distinct from other frankincense-producing Boswellia species.

## Synergistic Combinations

Boswellic acids from Boswellia species are commonly combined with curcumin (from Curcuma longa) in [anti-inflammatory](/ingredients/condition/inflammation) formulations, as both compounds inhibit the NF-κB pathway and 5-LOX/COX-2 enzymes through complementary mechanisms, producing additive to synergistic reductions in inflammatory biomarkers observed in B. serrata combination trials. The monoterpene α-pinene present in B. papyrifera essential oil may enhance oral bioavailability of co-administered boswellic acids by modulating [intestinal permeability](/ingredients/condition/gut-health), a phenomenon documented for terpenoid-polyphenol combinations. Traditional East African formulations sometimes combine olibanum resin with myrrh (Commiphora species), a pairing with documented in vitro [antimicrobial](/ingredients/condition/immune-support) synergy relevant to the anti-TB traditional application.

## Frequently Asked Questions

### What makes Boswellia papyrifera different from Boswellia serrata?

Boswellia papyrifera has a distinct boswellic acid profile compared to B. serrata: it completely lacks β-boswellic acid and contains relatively low β-keto-boswellic acid (0.46%), whereas B. serrata contains measurable amounts of both. Additionally, B. papyrifera is native to northeastern Africa and Sudan rather than the Indian subcontinent, and has been used in Arabic and East African traditional medicine rather than Ayurveda. This compositional difference means clinical data from B. serrata supplements cannot be directly applied to B. papyrifera.

### What is Boswellia papyrifera used for in traditional medicine?

In traditional Arabic and East African medicine, the dried resin of Boswellia papyrifera — known as olibanum — is used primarily for respiratory conditions including tuberculosis-like chest infections, as well as wound healing, inflammatory joint pain, and fever management. Ethiopian and Eritrean traditional healers prepare resin decoctions or employ smoke inhalation from burned resin for chest complaints. These uses are ethnobotanically documented but have not yet been validated in controlled clinical trials.

### Does Boswellia papyrifera have anti-tuberculosis activity?

Traditional Arabic medicine has employed Boswellia papyrifera olibanum resin as part of anti-TB treatments, and in vitro studies confirm that solvent extracts of the resin possess antimicrobial activity, with chloroform fractions showing the greatest potency. However, no controlled clinical trials have evaluated B. papyrifera specifically against Mycobacterium tuberculosis in human subjects, so the anti-TB claim remains based on ethnopharmacological evidence and preliminary laboratory data. Research into its specific mechanisms against mycobacteria, including the possible role of its alkaloid fraction (44.6% in crude extracts), is ongoing.

### What are the main bioactive compounds in Boswellia papyrifera resin?

The primary bioactives are pentacyclic triterpenic boswellic acids, which constitute approximately 7.04% of total β-boswellic acids in the resin's lipophilic fraction (55–66% of total resin), along with novel stilbene glycosides from the bark and lupane-type triterpenes such as 3α-acetoxy-27-hydroxylup-20(29)-en-24-oic acid. The essential oil fraction contributes monoterpenes including limonene (4.7%) and α-pinene (2.1%), and diterpenes incensole acetate (1.7%) and incensole (0.7%). In crude plant extracts, alkaloids are the most concentrated phytochemical class at 44.6%, followed by tannins (35.2%) and flavonoids (27.0%).

### Is Boswellia papyrifera safe to take as a supplement?

No human clinical safety trials have been conducted specifically for Boswellia papyrifera, so definitive safety conclusions cannot be drawn. By analogy with the closely related B. serrata, standardized resin extracts at moderate doses are generally considered well tolerated, with mild gastrointestinal side effects being the most common concern. Caution is warranted due to the high alkaloid content in crude extracts and the potential for boswellic acids to interact with CYP3A4-metabolized drugs; use during pregnancy is not recommended without medical supervision.

### How does Boswellia papyrifera compare to other Boswellia species for antimicrobial effects?

Boswellia papyrifera demonstrates particularly potent antimicrobial activity, with its chloroform extract showing the broadest spectrum of activity against various microorganisms compared to other species. The resin's traditional use in Arabic medicine specifically targets Mycobacterium tuberculosis-related conditions, making it distinctive among Boswellia varieties for antimicrobial applications. This focused antimicrobial profile sets it apart from Boswellia serrata, which is primarily valued for anti-inflammatory effects.

### What extraction method produces the most effective Boswellia papyrifera extract for antimicrobial use?

Chloroform extraction of Boswellia papyrifera resin produces the most effective antimicrobial fraction, demonstrating the broadest spectrum of activity against microbial pathogens. Petroleum ether and ethanol extracts also exhibit antimicrobial properties but with narrower activity ranges compared to the chloroform fraction. The solvent used in extraction significantly influences which bioactive compounds are concentrated, directly affecting the supplement's antimicrobial efficacy.

### Who should consider Boswellia papyrifera supplementation for its antimicrobial benefits?

Individuals seeking natural antimicrobial support, particularly those interested in traditional approaches to respiratory and TB-associated wellness, may benefit from Boswellia papyrifera supplementation. Those already using anti-inflammatory herbs may find additional value in this species due to its dual antimicrobial and anti-inflammatory properties from boswellic acids. However, anyone with active tuberculosis or serious infections should consult a healthcare provider before use, as supplements should complement rather than replace conventional treatment.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*